NTRK1 Antibody

What is NTRK1 and what are its primary biological functions?

NTRK1 (neurotrophic receptor tyrosine kinase 1), also known as TrkA, is a high-affinity nerve growth factor (NGF) receptor with essential roles in the development and maintenance of cholinergic neurons. The protein has a molecular weight of approximately 87.5 kilodaltons and undergoes various post-translational modifications .

NTRK1 functions primarily as a receptor tyrosine kinase involved in the development and maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation, and survival of sympathetic and nervous neurons. Upon binding its primary ligand NGF, NTRK1 undergoes homodimerization, autophosphorylation, and activation, subsequently recruiting and activating downstream effectors including SHC1, FRS2, SH2B1, SH2B2, and PLCG1 . These interactions regulate overlapping signaling cascades that drive cell survival and differentiation.

While NTRK1 is predominantly expressed in cholinergic neurons of the brain (including the basal forebrain and striatum), research has documented more widespread distribution in non-basal forebrain cholinergic cells . Recent studies have also identified NTRK1 as a molecular marker of the paraventricular thalamic nucleus (PVT), an emerging center for emotional processing .

What criteria should researchers consider when selecting an NTRK1 antibody?

When selecting an NTRK1 antibody, researchers should consider:

• Validation status: Prioritize antibodies with documented validation using knockout controls. Recent research tested seven commercial antibodies against NTRK1 and found only one demonstrated clear specificity in western blotting when tested against Ntrk1 knockout mouse tissue .

• Application compatibility: An antibody that works well for western blotting may not perform optimally for immunohistochemistry. In one study, researchers identified that antibody #06-574 showed specificity in western blotting and subsequently demonstrated its utility in immunohistochemistry applications .

• Immunogen information: Consider the specific region of NTRK1 used as the immunogen. For example, antibodies targeting the extracellular domain (e.g., amino acids a1-416) have shown greater reliability in some studies .

• Cross-reactivity profiles: Verify reactivity across species relevant to your research. Commercial antibodies often specify reactivity with human, mouse, and rat NTRK1, with predicted reactivity in other species based on sequence homology .

• Lot-to-lot consistency: Quality differences between antibody lots can significantly affect specificity, especially with polyclonal antibodies. Researchers noted: "Quality differences between various antibodies can affect their specificity, especially in the case of polyclonal antibodies... Thus, the results obtained here may not apply to antibodies from other lots or suppliers, even though product names and catalog numbers are identical" .

How can researchers validate NTRK1 antibodies for experimental applications?

Validation of NTRK1 antibodies should employ multiple approaches:

• Genetic controls: The gold standard approach uses tissues or lysates from Ntrk1 knockout animals as negative controls. Research demonstrated that specific bands disappeared in knockout samples when using an appropriately specific antibody .

• Application-specific validation: Researchers should validate antibodies for each specific application:

  • For western blotting: Compare band patterns between wild-type and knockout samples

  • For immunohistochemistry: Compare staining patterns with in situ hybridization data and evaluate known anatomical distribution patterns

• Multiple antibody approach: When knockout controls aren't available, compare results from multiple antibodies targeting different epitopes of NTRK1.

• Correlation with gene expression data: Compare protein detection with known mRNA expression patterns. In one study, "The regions with intense signals in cell bodies and staining patterns substantially matched the ISH images; regions included the striatum, caudate putamen, olfactory tubercle, globus pallidus, piriform cortex, nucleus accumbens, the horizontal and vertical limbs of the diagonal band of Broca, ventral tegmental nucleus, and medial vestibular nucleus" .

• Band size verification: For western blotting, verify that detected bands match expected molecular weights, considering post-translational modifications: "the molecular weight (MW) of some bands matched the size of the Ntrk1 protein, which was predicted or reported to be approximately 80-140 kDa, depending on post-translational modifications such as glycosylation and phosphorylation" .

What are the optimal protocols for western blotting with NTRK1 antibodies?

For optimal western blotting results with NTRK1 antibodies:

• Sample preparation:

  • Fresh tissue preparation is critical for maintaining protein integrity

  • Brain lysates should be prepared with protease and phosphatase inhibitors

  • For developmental studies, embryonic (E18) brain samples may show different band patterns compared to adult samples

• Expected band patterns:

  • Full-length NTRK1 appears at approximately 110 kDa in adult brain samples

  • Multiple bands may appear in embryonic samples due to developmental isoforms

  • Heterozygous samples show reduced band intensity, providing additional validation of specificity

• Positive controls:

  • Include samples from tissues known to express NTRK1 (striatum, basal forebrain)

  • When available, use overexpression systems as positive controls

• Antibody concentration optimization:

  • Titrate antibody concentrations to determine optimal dilutions

  • Consider longer exposure times for detecting low-abundance phosphorylated forms

• Phosphorylated NTRK1 detection considerations:

  • Antibodies targeting phosphorylated forms may require specific activation conditions

  • Some commercial antibodies (e.g., #9141 and sc-8058) have shown limited detection of phospho-NTRK1 under physiological conditions

What strategies improve immunohistochemical detection of NTRK1 in brain tissue?

For successful immunohistochemical detection of NTRK1:

• Tissue preparation:

  • Optimal fixation is critical - perfusion fixation with 4% paraformaldehyde is standard

  • Antigen retrieval methods should be optimized (heat-induced vs. enzymatic)

  • Section thickness (typically 30-40 µm for floating sections) affects antibody penetration

• Antibody selection and verification:

  • Use antibodies validated for immunohistochemistry (IHC-P or IHC-F applications)

  • Validate antibody specificity using knockout tissue when available

  • Compare staining patterns with in situ hybridization data for the same regions

• Expected expression patterns:

  • Strong signal should be observed in known NTRK1-expressing regions: striatum, basal forebrain, and specific nuclei

  • The paraventricular thalamic nucleus shows a characteristic anterior-posterior gradient (high anterior, low posterior expression)

  • Limited signal should be observed in regions with low expression (hippocampus, entorhinal cortex)

• Signal amplification considerations:

  • Tyramide signal amplification can enhance detection of low-abundance NTRK1

  • Secondary antibody selection should match the host species of the primary antibody

• Controls and counterstaining:

  • Include primary antibody omission controls

  • Counterstain with neuronal markers or cholinergic markers for colocalization studies

  • When possible, include positive and negative tissue controls

How should researchers interpret multiple bands in NTRK1 western blots?

Multiple bands in NTRK1 western blots require careful interpretation:

What approaches help differentiate specific from non-specific staining in immunohistochemistry?

To distinguish specific from non-specific staining:

• Anatomical verification:

  • Compare staining patterns with known NTRK1 expression in specific brain regions

  • Strong signal should be observed in striatum, basal forebrain, and the paraventricular thalamic nucleus

  • "Distinct signals were observed in regions with known Ntrk1 expression, such as the striatum and basal forebrain"

• Comparison with gene expression data:

  • "The regions with intense signals in cell bodies and staining patterns substantially matched the ISH images"

  • Regions lacking mRNA expression should show minimal antibody staining

• Cellular localization analysis:

  • NTRK1 should show both membrane and cytoplasmic localization

  • Nuclear staining is likely non-specific in most contexts

• Gradient verification in specific regions:

  • "The characteristic expression pattern of Ntrk1 in the paraventricular thalamic nucleus (PVT) was verified at the protein level, with high and low expression levels in the anterior and posterior PVT, respectively"

  • This gradient pattern provides an internal validation of specificity

• Knockout tissue controls:

  • When available, compare staining between wild-type and knockout tissues

  • All specific signals should be absent in knockout tissues

What strategies can resolve discrepancies between western blotting and immunohistochemistry results?

When NTRK1 antibodies work for one application but not another:

• Epitope accessibility differences:

  • Fixation can mask epitopes important for immunohistochemistry

  • Denaturation in western blotting exposes epitopes that may be hidden in native proteins

  • "Antibodies that work for western blotting sometimes do not work for immunohistochemistry, and vice versa"

• Application-specific optimization:

  • For western blotting: Optimize protein extraction, denaturation conditions, and transfer efficiency

  • For immunohistochemistry: Test multiple antigen retrieval methods (heat-induced vs. enzymatic)

• Antibody selection considerations:

  • Consider antibodies specifically validated for your application of interest

  • Monoclonal antibodies may offer greater specificity but reduced epitope accessibility

  • Polyclonal antibodies offer multiple epitope recognition but may show increased background

• Tissue preparation adjustments:

  • For recalcitrant antibodies in IHC, try different fixation protocols (shorter fixation times)

  • For difficult western blotting, try modified extraction buffers or gentler denaturation

• Cross-validation approaches:

  • Validate protein expression using complementary techniques (qPCR, in situ hybridization)

  • When possible, use multiple antibodies targeting different epitopes

How does NTRK1 influence immune responses in cancer and immunotherapy contexts?

NTRK1 plays significant roles in modulating immune responses:

How does NTRK1 mediate cellular cross-talk in neural and tumor microenvironments?

NTRK1 facilitates important cellular interactions:

• Neuroblastoma-Schwann cell interactions:

  • NTRK1 expression in neuroblastoma cells significantly enhances proliferation of Schwann cells

  • "The highest growth rates with significantly enhanced proliferative activity of Schwann cells were achieved when medium conditioned by SY5Y-NTRK1 cells was added"

  • This effect is NTRK1-specific, as "proliferation of Schwann cells incubated with CM from SY5Y-vec control cells decreased"

• NRG1-mediated signaling mechanisms:

  • NTRK1-expressing cells promote Schwann cell proliferation through NRG1 release

  • "Inhibiting NRG1 in this way reduced Schwann cell proliferation by 50% after three days"

  • Neutralizing antibodies against NRG1 "almost completely abolished migratory capacity of Schwann cells"

• Migratory behavior modulation:

  • "At day 9, 45 percent of Schwann cells migrated through the membrane when cultured with NTRK1-positive cells, while SY5Y-vec cells did not significantly induce Schwann cell migration"

  • NTRK1 expression is crucial for "stimulating and maintaining both the proliferative activity and migratory capacity of Schwann cells in the tumor stroma"

• In vivo tumor growth influence:

  • "NTRK1 induction in neuroblastoma xenografts mixed with primary SC also significantly reduced tumor growth in vivo"

  • "The overexpression of Ntrk1 significantly enhanced tumor size in vivo" , demonstrating context-dependent effects

• Therapeutic implications:

  • Understanding NTRK1-mediated cellular cross-talk offers potential therapeutic targets

  • Blocking specific downstream mediators (like NRG1) may alter cellular interactions in pathological states

What methodological approaches best capture NTRK1 fusion detection in cancer research?

NTRK1 fusion detection requires specialized approaches:

• Database curation challenges:

  • Current databases show incomplete overlap of NTRK fusions, necessitating "an organized and focused curation effort"

  • From one systematic review, "94 unique NTRK fusions were logged along with their presence across each database"

• Fusion orientation verification:

  • Most fusions (n=74) feature NTRK as the 3' partner (5' X ∷ 3' NTRK)

  • 20 were reported with NTRK as the 5' partner (5' NTRK ∷ 3' X)

  • Careful validation of reported fusions is critical as "8 [were] spurious entries, of which 6 were the result of data entry errors where fusion orientation was listed with NTRK as the 3′ partner in the paper, but logged incorrectly in the database"

• Antibody-based detection methods:

  • Pan-TRK antibodies can detect fusion proteins in IHC

  • Verification requires molecular techniques including RT-PCR or RNA sequencing

  • Fusion-specific antibodies may offer increased specificity but require knowledge of specific breakpoints

• Reference verification importance:

  • Always verify primary literature sources when identifying putative NTRK fusions

  • "Careful review identified the absence of NTRK1-CD5 from the cited manuscript and NTRK-Fc was a representation of a recombinant fusion created for experimental purposes"

• Multi-platform validation approaches:

  • Combine IHC screening with confirmatory molecular testing

  • RNA-based methods offer greater sensitivity for fusion detection

  • Next-generation sequencing approaches allow unbiased detection of novel fusions

What emerging applications of NTRK1 antibodies might researchers consider?

• Therapeutic antibody development:

  • NTRK1-targeting antibodies could potentially modulate immunotherapy responses

  • Antibodies targeting specific NTRK1 domains might selectively inhibit pathological signaling

• Single-cell analysis applications:

  • Validated antibodies enable flow cytometry and mass cytometry studies of NTRK1 in heterogeneous populations

  • Combining with other neural markers could identify novel NTRK1-expressing cell populations

• In vivo imaging approaches:

  • Conjugated antibodies might enable targeted imaging of NTRK1-expressing tissues

  • Potential applications in detecting NTRK1-positive tumors or monitoring therapeutic responses

• Functional blocking studies:

  • Neutralizing antibodies against NTRK1 could help dissect signaling pathways

  • Domain-specific blocking antibodies might reveal differential roles of NTRK1 structural elements

• Comprehensive antibody validation frameworks:

  • Development of standardized validation protocols across applications

  • Creation of antibody validation registries specific to neuroscience applications